Clinical Trials

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT04923893 2026-04-13

CARTITUDE-5

743 enrolled

Phase 2 Active not recruiting

Multiple Myeloma

NCT06577025 2026-04-13

aMMbition

43 enrolled

Multiple Myeloma

NCT07149857 2026-04-13

CARTITUDE-10

Phase 2 Recruiting

60 enrolled

Multiple Myeloma

NCT06413498 2026-03-27

iMMagine-3

Phase 3 Recruiting

450 enrolled

Multiple Myeloma

NCT06153251 2026-03-18

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

Phase 1 Recruiting

187 enrolled

Phase 3 Active not recruiting

Multiple Myeloma

NCT06045806 2026-03-05

KarMMa-9

79 enrolled

Multiple Myeloma

NCT04674813 2026-02-09

A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma

130 enrolled

Multiple Myeloma

NCT05182073 2025-12-12

FT576 in Subjects With Multiple Myeloma

31 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05722418 2025-09-25

CaMMouflage

Phase 1 Recruiting

50 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Multiple Myeloma

NCT06119685 2025-06-03

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Phase 1/2 Recruiting

128 enrolled

Lymphoma, Non-Hodgkin, Multiple Myeloma, Hematologic Neoplasms

NCT03994705 2025-05-15

Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma

20 enrolled 12 charts

Multiple Myeloma

NCT05347485 2025-04-25

A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma

86 enrolled 19 charts

Multiple Myeloma

NCT01539083 2025-02-04

VCAT

Phase 3 Completed

256 enrolled 13 charts

Multiple Myeloma

NCT03448978 2024-07-01

Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma

32 enrolled

Multiple Myeloma

NCT05000450 2024-06-28

Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

Phase 1/2 Terminated

6 enrolled

Multiple Myeloma

NCT02513186 2024-01-29

Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation

90 enrolled

Multiple Myeloma

NCT04025216 2024-01-24

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

BreastGynecologicPlasma cellThoracic

16 enrolled

Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Multiple Myeloma, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT02188368 2023-11-03

Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients

Phase 2 Terminated

45 enrolled

Multiple Myeloma

NCT02206425 2023-10-31

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Phase 1/2 Completed

45 enrolled

Multiple Myeloma, Recurrence

NCT03318861 2023-10-19

Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma

17 enrolled 15 charts

Multiple Myeloma

NCT04171843 2023-09-21

A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma

48 enrolled

Multiple Myeloma

NCT04614636 2023-09-21

FT538 in Subjects With Advanced Hematologic Malignancies

Other hematologic neoplasmPlasma cell

42 enrolled

Multiple Myeloma, Leukemia, Myeloid, Acute, Neoplasms, Plasma Cell

NCT04613557 2023-08-31

IMMUNICY-1

Phase 1 Active not recruiting

18 enrolled

Multiple Myeloma, Recurrence

NCT04196491 2023-08-23

KarMMa-4

13 enrolled

Phase 1 Active not recruiting

Multiple Myeloma

NCT04093596 2023-08-14

UNIVERSAL

132 enrolled

Multiple Myeloma

NCT01881789 2022-11-14

Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma

Phase 1/2 Terminated

22 enrolled 17 charts

Multiple Myeloma

NCT03168438 2022-01-11

Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma

6 enrolled 19 charts

Multiple Myeloma, Neoplasms, Recurrence

NCT02951819 2021-10-08

A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma

101 enrolled 17 charts

Phase EARLY_PHASE1 Unknown

Multiple Myeloma

NCT03943472 2021-08-31

BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma

10 enrolled

Phase EARLY_PHASE1 Unknown

Multiple Myeloma

NCT04626752 2020-11-13

CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

50 enrolled

Multiple Myeloma, Recurrence

NCT02046070 2019-07-17

Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma

148 enrolled 38 charts

Multiple Myeloma

NCT01660750 2017-10-18

11-MM-01

29 enrolled

Multiple Myeloma

NCT01980589 2017-05-30

CHAMPION 2

22 enrolled 11 charts

Multiple Myeloma

NCT01094548 2016-02-22

Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy

34 enrolled 12 charts

Multiple Myeloma

NCT00908232 2015-01-15

SEQUENTIAL

163 enrolled 11 charts

Multiple Myeloma, Disease Progression, Bone Marrow Neoplasms

NCT00833560 2014-11-21

A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy

401 enrolled 10 charts

Multiple Myeloma

NCT00813150 2014-08-15

Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma

Phase 3 Completed

96 enrolled 12 charts

Multiple Myeloma, Neoplasms

NCT00507442 2013-07-26

EVOLUTION

Phase 1/2 Completed

158 enrolled 17 charts

Multiple Myeloma

NCT00531453 2012-01-26

A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma

98 enrolled 9 charts